FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/07/071469 [Registered on: 29/07/2024] Trial Registered Prospectively
Last Modified On: 27/07/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Single Arm Study 
Public Title of Study   Role of Brahmdandi ( Tricholepis glaberrima, rasanjan and mishri in menorrhagia 
Scientific Title of Study   Pharmacotherapeutic and Pahrmacognostical Study of Brahmdandyadi yoga in the management of Raktapradara (Menorrhagia) 
Trial Acronym  nill 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr. Nikita panwar 
Designation  Ph.D scholar and assistant professor 
Affiliation  PGIA, DSRRAU, Jodhpur 
Address  PG Department of Dravyaguna Vigyan, PGIA, DSRRAU, Nagaur Road, Karwad, Jodhpur

Jodhpur
RAJASTHAN
342037
India 
Phone  9784617992  
Fax    
Email  ranusingh936@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Prof. Chandan 
Designation  Professor and HOD 
Affiliation  PGIA, DSRRAU, Jodhpur 
Address  Room number 13, PG Department of Dravyaguna Vigyan, PGIA, DSRRAU, Jodhpur

Jodhpur
RAJASTHAN
342037
India 
Phone  9784617992  
Fax    
Email  chandan_singh4@yahoo.com  
 
Details of Contact Person
Public Query
 
Name  Nikita panwar 
Designation  PhD scholar and Assistant professor 
Affiliation  PGIA, DSRRAU, Jodhpur 
Address  Room number 8, PG Department of Dravyaguna Vigyan, PGIA, DSRRAU, Jodhpur

Jodhpur
RAJASTHAN
342037
India 
Phone  9784617992  
Fax    
Email  ranusingh936@gmail.com  
 
Source of Monetary or Material Support  
Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University,Nagaur Road, Karwad, Jodhpur, Rajasthan. India. Pin code 342037 
 
Primary Sponsor  
Name  Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University Jodhpur 
Address  Post Graduate Institue of Ayurved, Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University, Nagaur road, Karwad, Jodhpur, Rajasthan, India. Pin code 342037 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
Prof Chandan Singh  PGIA, Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University, Nagaur road, Karwad, Jodhpur, Rajasthan  
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Nikita Panwar  Sanjeevani Ayurved Hospital  Sanjeevani Ayurved Hospital, Dravyaguna OPD, Room number 10, DSRRAU Nagaur road karwad jodhpur.
Jodhpur
RAJASTHAN 
9784617992

ranusingh936@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
IEC, PGIA, DSRRAU, Jodhpur  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:N920||Excessive and frequent menstruation with regular cycle. Ayurveda Condition: YONIROGAH/YONI-VYAPADAH,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Intervention ArmDrugClassical(1) Medicine Name: Brahmdandyadi Yog, Reference: Siddh Bhaishajya Mani Mala,asrigdara chikitsa, shloka no. 5,6. page no. 338 , Route: Oral, Dosage Form: Churna/ Powder, Dose: 3(g), Frequency: bd, Bhaishajya Kal: Adhobhakta, Duration: 3 Months, anupAna/sahapAna: Yes(details: -water), Additional Information: -
 
Inclusion Criteria  
Age From  15.00 Year(s)
Age To  45.00 Year(s)
Gender  Female 
Details  1. Well diagnosed and confirm patient of Raktapradara.
2. Patients aged between menarche and menopause of life and willing to participate in trial.
3. Excessive per vaginal bleeding for more than 2 consecutive cycles.
4. Patients suffering from PCOD. 
 
ExclusionCriteria 
Details  1. Patients having bleeding from carcinoma or big fibroid like conditions.
2. Patients having bleeding due to abortion.
3. Patients having bleeding from sites other than uterus.
4. Patient having coagulation disorders.
5. Patients using IUCDs.
6. Patient having diabetes, thyroid dysfunction. 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
reduction in bleeding through number of used pads per day during menstruation  3 months 
 
Secondary Outcome  
Outcome  TimePoints 
pharmacognostical and phytochemical study of drug  2 months 
 
Target Sample Size   Total Sample Size="100"
Sample Size from India="100" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2 
Date of First Enrollment (India)   14/08/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   Menorrhagia is a condition characterized by abnormally heavy menstrual bleeding. Clinical studies on menorrhagia aim to understand its causes, evaluate potential treatments, and improve the overall management of the condition.
If left untreated, it can lead to complications such as anemia, weakness, and other serious health issues caused by excessive bleeding. so this study has been planned to evaluate the role of herbal medicines in management of menorrhagia.
It is a single arm open labelled interventional study for management of menorrhagia through herbal preparation Brahmdandyadi Yog ( Brahmdandi - Tricholepis glaberrima, Rasanjan - Extract of Berberis aristata and mishri) to evaluate its efficacy. sample size is 100 and trial will be done for three months.
 
Close